Evidence map›Paper›PMID 42883956›Full record

ArticleInternational journal of molecular sciences2026

Molecular Mechanisms Implicated in Myogenic Differentiation of Human Alveolar Mucosa-Derived Cells.

Maksim Sorokin, Anton Buzdin, Anastasia Guryanova, Alexander Gudkov, Alexander Modestov, Maria Suntsova, Ilya Eremin, Andrey Pulin, Nastasia Kosheleva, Alla Zorina and 7 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maksim SorokinInstitute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.ORCID 0000-0001-7685-3446
Anton BuzdinInstitute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Anastasia GuryanovaInstitute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Alexander GudkovInstitute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Alexander ModestovInstitute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.ORCID 0000-0002-1531-7161
Maria SuntsovaInstitute of Personalized Oncology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Ilya EreminPetrovsky National Research Center of Surgery, Moscow 119991, Russia.
Andrey PulinPirogov National Medical and Surgical Center, Moscow 105203, Russia.ORCID 0000-0002-9499-4979
Nastasia KoshelevaInstitute for Regenerative Medicine, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Alla ZorinaArtgen Biotech, Moscow 119333, Russia.
Vadim ZorinArtgen Biotech, Moscow 119333, Russia.
Dmitry KudlayDepartment of Pharmacology, I.M. Sechenov First Moscow State Medical University, Moscow 119991, Russia.
Sergei BoichukDepartment of Pathology, Kazan State Medical University, Kazan 420012, Russia.ORCID 0000-0003-2415-1084
Maria VasilevaN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
Maria FedorovaN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
Svetlana VinokurovaN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.
Pavel KopninN.N. Blokhin National Medical Research Center of Oncology, Moscow 115522, Russia.ORCID 0000-0002-2078-4274

Funding

Russian Science Foundation grant no. 23-15-00433World-Class Research Centers "Digital biodesign and personalized healthcare" No 075-15-2022-304
6 · The paper itself

Abstract

Different approaches to skeletal muscle regeneration using progenitor cells are extensively studied as strategies for the treatment of muscle tissue pathologies. Recently, it was discovered that anatomically localized alveolar mucosa multipotent mesenchymal stromal cells (AMCs) are characterized by myogenic potential and high feasibility for muscle tissue recovery and regeneration. Although the resulting multinuclear myotubes express skeletal muscle-specific markers (skeletal myosin, actin, myogenin, and MyoD1), the exact molecular mechanism controlling myogenic differentiation of AMCs is still unclear and poorly scrutinized. In this research, we used a combination of large-scale transcriptome analysis and a bioinformatics approach to investigate molecular pathways and crucial nodes responsible for myogenic differentiation. We studied differentiation of AMC cells in 2D and 3D culture conditions and found core genes with significant expression changes during differentiation and compared them with skeletal muscle-derived stromal cells (SMCs). It appeared that differentiation of AMCs in 3D is significantly different from that in 2D. Moreover, differentiation of AMCs in 2D is closer to differentiation of SMCs in 2D than to AMCs in 3D. Unique properties of AMC differentiation in 3D may be attributed to a significant inhibition of the component of the PDGFRβ signaling pathway responsible for ruffle organization.

Indexed as

Cell DifferentiationMesenchymal Stem CellsMuscle DevelopmentCells, CulturedGene Expression ProfilingHumansMuscle Fibers, SkeletalMuscle, SkeletalSignal Transductionalveolar mucosa mesenchymal cellgene expressionintracellular molecular pathwaysmyogenesismyogenic regulatory factorsskeletal muscletranscriptional regulation network

Identifiers

PMID42883956
PMCPMC13665378

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.